Science

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Guilherme Nader Marta/X

Feb 9, 2025, 15:31

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared an article on X:

“If you’re interested in the topic, don’t miss our full review on the current role of anthracyclines in early breast cancer treatment.

We analyze efficacy, toxicity & pt selection, including data recently presented on the predictive value of Oncotype & Mamma Print.”

“Honored to share our article in the NEJM Breast Cancer Update, discussing two perspectives on anthracycline use in breast cancer—a long-debated topic that remains highly relevant today Grateful to co-author this work with Prof. Martine Piccart.”

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Redefining the role of anthracyclines in early breast cancer treatment.

Authors: Guilherme Nader-Marta, et al.

Guilherme Nader Marta: The current role of anthracyclines in early breast cancer treatment

Anthracyclines Breast Cancer cancer Dana-Farber Cancer Institute fight against cancer Global fight against cancer Guilherme Nader Marta OncoDaily Oncology Oncotype

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial